Botox, a brand name for botulinum toxin type A, includes subtypes, with type B (BTX-B) known as Neurobloc in the EU and Myobloc in the USA. Primarily recognized for its cosmetic applications, Botox is also marketed as Vistabel in the EU and Dysport.
In the 1950s, botulinum toxin type A (BTX-A) was used in small injections to reduce overactive muscle activity and explored for cosmetic treatments. In 1989, Allergan Inc. received FDA approval for Botox in the U.S. Cosmetic use approval followed in 2002, after its cosmetic effects were discovered.
Botulinum toxin type A (BTX-A), produced by bacteria, works by interfering with nerve impulses when injected. It’s used in non-surgical cosmetic treatments to reduce lines and wrinkles, but its effects are temporary, requiring repeat injections.
Botox treats glabellar lines (frown lines between the eyebrows), excessive underarm sweating, spasticity, muscle disorders, and obesity. Research continues for new treatments using Botox.
As a prescription drug, Botox should be administered by a qualified physician in a controlled setting like a doctor’s office. This ensures monitoring of immediate side effects. “Botox parties” are not recommended because of these safety concerns.
In the U.S., Botox is licensed for single-use vials to prevent contamination. Sharing vials to reduce costs is discouraged. Consuming alcohol after an injection can also negatively impact results. It’s advised to avoid rubbing the face and to remain upright for several hours post-injection to prevent Botox from migrating outside the targeted area.
A common side effect is droopy eyelids, caused by paralyzed eyelid muscles. This usually lasts only a few days. Due to Botox’s neurotoxin base, careful administration is crucial. Consult your physician about the frequency of injections, generally between four to eight months, but no less than three months apart.